# Sixfold Bioscience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sixfold-bioscience

- Industry: Biotechnology
- Headquarters: London, UK
- Website: www.sixfold.bio
- Total disclosed funding: $10M
- Latest round: Seed (Dec 2, 2021)
- Investors on record: 4

## About

Founded in 2017 by CEO Dr. George Foot and based in London, UK, Sixfold Bioscience Ltd operates as a developer of RNA therapeutics for cell diseases. In December 2021, Sixfold Bioscience Ltd raised GBP 7.8 million in seed funding from new investor Cantos Ventures, with participation from returning investors LombardStreet Ventures, Pi Campus, and Y Combinator. 

Sixfold develops programmable drug delivery systems and short interfering RNA for gene silencing and messenger RNA for gene expression. Sixfold’s Mergo platform consists of the RNA therapeutic and biocompatible building blocks that are assembled using chemistry, screened and then tested to modulate the pharmacokinetic and pharmacodynamic properties of the system and to target selected cell types. The Mergo system then learns the combination for delivery to a given tissue. 

Sixfold Bioscience Ltd will use the funding to support the continued development of its Mergo® RNA therapeutics delivery platform.

## Funding rounds

- Seed, Dec 2, 2021, $10M — Y Combinator, Cantos Ventures, Pi Campus, Lombardstreet Ventures

## Investors

- Y Combinator (https://capitalatlas.ai/funds/y-combinator) — Seed
- Cantos Ventures (https://capitalatlas.ai/funds/cantos-ventures) — Seed
- Pi Campus (https://capitalatlas.ai/funds/pi-campus) — Seed
- Lombardstreet Ventures (https://capitalatlas.ai/funds/lombardstreet-ventures) — Seed